These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 25518754)

  • 1. Evaluation of opioid modulation in major depressive disorder.
    Ehrich E; Turncliff R; Du Y; Leigh-Pemberton R; Fernandez E; Jones R; Fava M
    Neuropsychopharmacology; 2015 May; 40(6):1448-55. PubMed ID: 25518754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
    Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
    Fava M; Thase ME; Trivedi MH; Ehrich E; Martin WF; Memisoglu A; Nangia N; Stanford AD; Yu M; Pathak S
    Mol Psychiatry; 2020 Jul; 25(7):1580-1591. PubMed ID: 30374191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
    Fava M; Memisoglu A; Thase ME; Bodkin JA; Trivedi MH; de Somer M; Du Y; Leigh-Pemberton R; DiPetrillo L; Silverman B; Ehrich E
    Am J Psychiatry; 2016 May; 173(5):499-508. PubMed ID: 26869247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.
    Thase ME; Stanford AD; Memisoglu A; Martin W; Claxton A; Bodkin JA; Trivedi MH; Fava M; Yu M; Pathak S
    Neuropsychopharmacology; 2019 Dec; 44(13):2268-2276. PubMed ID: 31254971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat.
    Smith KL; Cunningham JI; Eyerman DJ; Dean RL; Deaver DR; Sanchez C
    Neuropharmacology; 2019 Mar; 146():316-326. PubMed ID: 30448421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
    Ragguett RM; Rong C; Rosenblat JD; Ho RC; McIntyre RS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):475-482. PubMed ID: 29621905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder.
    Bidlack JM; Knapp BI; Deaver DR; Plotnikava M; Arnelle D; Wonsey AM; Fern Toh M; Pin SS; Namchuk MN
    J Pharmacol Exp Ther; 2018 Nov; 367(2):267-281. PubMed ID: 30108159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
    Pathak S; Vince B; Kelsh D; Setnik B; Nangia N; DiPetrillo L; Puhl MD; Sun L; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):218-228. PubMed ID: 30476361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3).
    Zajecka JM; Stanford AD; Memisoglu A; Martin WF; Pathak S
    Neuropsychiatr Dis Treat; 2019; 15():795-808. PubMed ID: 31040679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review.
    Serafini G; Adavastro G; Canepa G; De Berardis D; Valchera A; Pompili M; Nasrallah H; Amore M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30111745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats.
    Burke NN; Ferdousi M; Deaver DR; Finn DP; Roche M; Kelly JP
    Neuropharmacology; 2019 Mar; 146():327-336. PubMed ID: 30553825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
    Setnik B; Sommerville K; Goli V; Han L; Webster L
    Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
    Peckham AM; De La Cruz A; Dufresne RL
    Ment Health Clin; 2018 Jul; 8(4):175-183. PubMed ID: 30155392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
    Möller HJ; Demyttenaere K; Olausson B; Szamosi J; Wilson E; Hosford D; Dunbar G; Tummala R; Eriksson H
    World J Biol Psychiatry; 2015 Oct; 16(7):483-501. PubMed ID: 25602163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
    Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
    Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.